Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

Dr. Eric Verdin, Advisor to Genflow Biosciences (LON:GENF) (OTCQB:GENFF), had the privilege of addressing the Senate Special Committee on Aging last week, where he provided insights on the administration’s proposed budget cuts to the National Institutes of Health. See the clip here:

Meet the #GENFTeam Dr. Peter King-Lewis, Non-Executive Director of Genflow Biosciences (LON:GENF) (OTCQB:GENFF) Dr. King-Lewis, a former Submarine Seaman Officer and Diver in The Royal Navy, initiated his medical career at St. Bartholomew’s Hospital in London. Dr. King-Lewis is an HSE Approved Medical Examiner of Divers with a keen interest in hyperbaric medicine, bioidentical hormones, and acupuncture alongside conventional medicine. Additionally, he established and manages OfficeGP Ltd, providing primary care services in workplaces, and has held leadership roles in organizations such as The Independent Doctors Federation and the Chelsea Clinical Society for over twenty-seven years. Learn more about the Genflow team here: https://loom.ly/HqJZHZs #GENF #Team #director #biotech #longevity

Meet the #GENFTeam Dr Guy Charles Fanneau de la Horie, Non-Executive Director of Genflow Biosciences (LON:GENF) (OTCQB:GENFF) Over the last two decades, Guy-Charles has played a pivotal role in establishing and steering biotech executive teams. Throughout his tenures, he has exhibited remarkable proficiency in guiding companies through IPOs and securing multiple rounds of funding. Guy-Charles' extensive expertise in the biotech arena, spanning both public and private enterprises, encompasses the successful introduction and sale of novel drugs in unexplored markets, along with the effective implementation of early access programs. Learn more about the GenFlow team here: https://loom.ly/HqJZHZs #GENF #director #biotech #longevity

Want to learn more about Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s innovative research? Check out our presentation! Find it here: https://loom.ly/cUN_1Wk #GENF #GENFF #aging #SIRT6

Meet the #GENFTeam Dr Yassine Bendiabdallah, Chairman of Genflow Biosciences (LON:GENF) (OTCQB:GENFF) Dr. Bendiabdallah (MPharm, PhD, IP) specializes in Functional Medicine and Healthy Ageing and has expertise in Bio-identical Hormone Therapy (BHRT). He worked as an anti-cancer drug discovery scientist with Cancer Research UK at University College London, resulting in multiple publications in academic journals. After years in academia, Dr. Bendiabdallah co-founded the Zen Healthcare group, a series of pharmacies and wellness clinics in London. He currently serves as Clinical Director, focusing on age reversal therapies, functional medicine, and intravenous micronutrient treatments. Additionally, he sits on the board of several healthcare companies. Learn more about the Genflow team here: https://loom.ly/HqJZHZs #GENF #chairman #biotech #aging #longevity

#WernerSyndrome is a genetic disorder that accelerates the aging process, causing early-onset symptoms such as hair loss, skin atrophy, and cataracts - typically associated with advanced age. Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is on a mission to help those suffering from the disease. As one of the few pioneers pursuing treatment options, we are advancing our groundbreaking #SIRT6 therapies. By targeting Werner Syndrome, we're not just developing a critical treatment for a rare disease - we're paving the way for broader anti #aging treatments that could improve the #healthspan for millions. Learn more about our disruptive research: https://loom.ly/uh0pGy8 #GENF #GENFF #SmallCap

Meet the #GENFTeam! CEO Dr. Eric Leire brings a diverse background across #pharma, #biotech, academia, and private equity. In addition to leading Genflow Biosciences (LON:GENF) (OTCQB:GENFF), Dr. Leire sits on the board of several biotech companies. Learn more: https://loom.ly/HqJZHZs #GENF #GENFF

MASH is a progressive #LiverDisease that not only causes significant liver damage but can also lead to #cirrhosis and, in some cases, liver cancer. Recent studies have highlighted how early intervention and treatment are crucial. Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is committed to making a difference. Our cutting edge #SIRT6 research targets the root causes of MASH to help combat disease progression and support liver health. #GENF's compound GF-1002 is just one way we're advancing solutions for better liver health and longer, healthier lives. Read about the most recent studies here: https://loom.ly/UskELU8 #GENFF #Biotech #Longevity #Healthspan

🧬 Why invest in Genflow Biosciences (LON:GENF) (OTCQB:GENFF)? 🧬 #GENF presents an opportunity for investors to back a #biotech company at the forefront of the #longevity sector. Our pioneering work with #SIRT6 has gained significant recognition, including being highlighted as "A Firm to Watch" by The Guardian. Learn more here: https://loom.ly/qLRb1jE

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s strong progress in 2024 and its priorities for 2025. Leire outlined four major projects: the MASH project targeting liver disease, advancements in sarcopenia, research on Werner syndrome through synthetic organ development, and the innovative life-extension project for dogs. Watch at #Proactive #ProactiveInvestors http://ow.ly/O9Mv105WgQX